Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554126 | 1.00 | CTSS (0.48) | CTSSCTSKMIFESR1ESR2 | |
| SCHEMBL1554122 | 1.00 | CTSS (0.48) | CTSSCTSKMIFESR1ESR2 | |
| SCHEMBL22201734 | 0.94 | CTSS (0.50) | CTSSCTSKMIFESR1ESR2 | |
| SCHEMBL15962588 | 0.92 | CTSS (0.49) | CTSSCTSKMIFESR1ESR2 | |
| SCHEMBL14254331 | 0.88 | CTSS (0.48) | CTSSCTSKTACR3S1PR3KLK5 | |
| SCHEMBL16244682 | 0.87 | CTSS (0.48) | CTSSCTSKMIFESR1ESR2 | |
| SCHEMBL1525552 | 0.87 | S1PR3 (0.52) | CTSSCTSKTACR3S1PR3TRPA1 | |
| SCHEMBL2426585 | 0.87 | NPSR1 (0.50) | CTSSCTSKTACR3S1PR3MAPT | |
| SCHEMBL21787638 | 0.87 | CTSS (0.47) | CTSSCTSKS1PR3KLK5TRPA1 | |
| SCHEMBL13808330 | 0.87 | NPSR1 (0.50) | CTSSCTSKTACR3S1PR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600728-B2 | Interleukin-17 inhibitors | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20260083708-A1 | IL-17 MODULATORS AND USES THEREOF | NNOCARE PHARMA INC (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2025243042-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILIN D | THE UNIVERSITY OF LIVERPOOL (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-12310945-B2 | Cyclohexylglycine derivatives as selective cytotoxic agents | MERCK SHARP & DOHME LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240252466-A1 | CYCLOHEXYLGYCINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC | 2024-08-01 | — | — | US | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | NOVARTIS AG (CH) | 2023-12-07 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| EP-1893634-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-8048881-B2 | Uding 4-aminocarbonyl-pyrimidine; vascular disorders; cardiovascular disorders; thrombosis; brain disorders; vision defects | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20110077265-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | IL17A, IL2, IL18 | CTSS 1100/4885CTSK 889/4885MIF 36/4885 |
| US-12310945-B2 | Cyclohexylglycine derivatives as selective cytotoxic agents | CD4, GZMB, GAA | CTSS 166/4885CTSK 372/4885MIF 856/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | CTSS 3419/4885CTSK 3425/4885MIF 114/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | CTSS 3419/4885CTSK 3425/4885MIF 114/4885 |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | CTSS 1847/4885CTSK 1525/4885MIF 4657/4885 |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | CTSS 4306/4885CTSK 4317/4885MIF 3150/4885 |
| US-20260083708-A1 | IL-17 MODULATORS AND USES THEREOF | IL17A, IL2, IL23R | CTSS 2855/4885CTSK 2954/4885MIF 147/4885 |
| US-20240252466-A1 | CYCLOHEXYLGYCINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | GZMB, CD4, CD74 | CTSS 108/4885CTSK 304/4885MIF 1683/4885 |
| US-20110077265-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC2 | CTSS 2271/4885CTSK 2243/4885MIF 2044/4885 |
| US-12600728-B2 | Interleukin-17 inhibitors | IL17A, IL2, IL1B | CTSS 2254/4885CTSK 2424/4885MIF 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.